Asep Darmawan
The American Chamber of Commerce in Taiwan (AmCham Taiwan) has released a comprehensive set of policy recommendations aimed at fortifying the nation’s pharmaceutical supply resilience and ensuring the long-term sustainability of the National Health Insurance (NHI) system. As Taiwan navigates a complex landscape of global political shifts and evolving economic pressures, the AmCham Pharmaceutical Committee emphasizes that the stability of the drug supply and the timely introduction of innovative therapies are critical to maintaining the health of Taiwanese citizens and the island’s standing as a global biotechnology hub. The committee’s position paper underscores a pivotal moment for Taiwan-U.S. cooperation, urging the government to adopt international best practices in drug pricing, reimbursement, and regulatory management to safeguard the "Healthy Taiwan" vision championed by the administration of President Lai Ching-te.
Contextual Background: The Evolution of Taiwans Healthcare Landscape
Taiwan’s National Health Insurance system, established in 1995, is globally renowned for its universal coverage, high efficiency, and low administrative costs. Covering over 99.9% of the population, the single-payer system has been a cornerstone of social stability. However, the system faces mounting financial pressure due to an aging population and the rising cost of breakthrough medical technologies. Currently, Taiwan’s healthcare spending as a percentage of GDP remains around 6% to 7%, significantly lower than the OECD average of approximately 9%.
Against this backdrop, the Lai Ching-te administration has introduced the "Healthy Taiwan" initiative, which sets ambitious goals such as reducing cancer mortality by one-third by the year 2030. To achieve these targets, the government has recognized the need for a more resilient pharmaceutical supply chain and increased investment in innovative medicines. The AmCham recommendations serve as a strategic roadmap to align these domestic goals with international standards, particularly as Taiwan seeks to deepen its economic and technological ties with the United States through frameworks like the U.S.-Taiwan Initiative on 21st-Century Trade.
Chronology of Recent Pharmaceutical Policy Developments
The current policy environment is the result of several years of incremental shifts and recent breakthrough agreements. In 2023, Taiwan and the United States made significant strides in trade relations, leading to duty-free treatment in the U.S. market for Taiwanese generic drugs and active pharmaceutical ingredients (APIs). This was followed by the 2024 presidential transition, where the incoming administration prioritized the "Five Trusted Industries," which includes biotechnology alongside semiconductors and artificial intelligence.
In early 2024, the Ministry of Health and Welfare (MOHW) and the National Health Insurance Administration (NHIA) announced plans to establish a dedicated Cancer Drugs Fund (CDF), with an initial target of reaching NT$10 billion by 2025. Furthermore, the Legislative Yuan recently completed amendments to Article 27 of the Pharmaceutical Affairs Act, shifting the focus of drug shortage management from reactive response to proactive risk monitoring. AmCham’s latest recommendations build upon these milestones, seeking to transition these "pilot" or "initial" phases into permanent, institutionalized mechanisms.
Establishing Formalized Policy Dialogue and International Alignment
A primary recommendation from the Committee is the formalization of a U.S.-Taiwan pharmaceutical policy dialogue mechanism. While ad-hoc communications exist, a structured, institutionalized platform would allow for regular exchanges between government representatives, industry leaders, and academic experts. This mechanism is envisioned to address emerging challenges such as regulatory alignment and the impact of global inflation on drug pricing. AmCham suggests that the NHIA conduct biannual consultations with the industry to review international economic trends, ensuring that Taiwan’s domestic policies do not become decoupled from global realities.
Beyond bilateral ties, the Committee advocates for the use of the Global Cooperation and Training Framework (GCTF). By leveraging this platform, Taiwan can showcase its healthcare governance strengths to a global audience, positioning itself as a leader in public health management while learning from the regulatory successes of partner nations.
A critical component of this alignment involves drug reimbursement conditions. Currently, there is a noted discrepancy between Taiwan’s NHI reimbursement criteria and international treatment guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN) or the European Society for Medical Oncology (ESMO). These gaps often manifest as restrictions on patient eligibility or limitations on the duration of treatment. AmCham notes that when domestic reimbursement lags behind international standards, it not only affects patient outcomes but also discourages multinational corporations from including Taiwan in global clinical trials, thereby hindering the accumulation of local clinical data.
Ensuring Fair R&D Cost-Sharing and Sustainable Funding
To support the launch of new drugs, AmCham emphasizes the need for evidence-based funding mechanisms. The proposed NT$10 billion Cancer Drugs Fund is a welcomed development, but its long-term efficacy depends on sophisticated budgeting. The Committee recommends the implementation of "horizon scanning"—an early-alert system that analyzes upcoming medical technologies to anticipate future budgetary needs. This proactive approach would move the NHI away from relying on historical data, which often fails to account for the rapid pace of biomedical innovation.
Data suggests that the delay between a drug’s global launch and its listing on the NHI reimbursement list can range from 12 to 24 months. To shorten this gap, AmCham suggests that Taiwan maintain and strengthen pricing premiums for drugs that undergo domestic clinical trials. Such incentives are vital for attracting R&D investment from global pharmaceutical giants, ensuring that Taiwanese patients gain earlier access to life-saving therapies.
The Committee also highlights the challenges of "international reference pricing." Many countries, including Taiwan, set drug prices based on a basket of other nations. Taiwan currently uses a "median of 10" reference countries. However, if Taiwan’s prices are compressed too aggressively through high rebates or spending caps, it can create a "downward spiral" effect, where a low price in Taiwan triggers price reductions in larger markets. This risk often forces global headquarters to deprioritize Taiwan in their launch sequences. AmCham calls for a pricing framework that balances financial sustainability with the need to remain an attractive market for innovation.
Lifecycle Management and Supply Resilience
The sustainability of the pharmaceutical ecosystem also depends on how drugs are managed throughout their lifecycle. A major point of contention is the Drug Expenditure Target (DET) system, a budget control mechanism used by the NHIA. The Committee points out that the baseline values for DET calculations have remained unchanged for over a decade, leading to distorted pricing signals that do not reflect actual market expenditures. Recalibrating this baseline is seen as essential for preventing the kind of extreme price erosion that can lead to drug shortages or the withdrawal of essential medicines from the market.
Furthermore, the protection of Intellectual Property Rights (IPR) remains a cornerstone of innovation. AmCham expressed concern that current price protection is often limited to primary patents, failing to recognize the broader scope of internationally accepted patent protections. When innovative medicines are subjected to premature price reductions despite holding valid patents, it undermines the incentive for companies to bring future innovations to Taiwan.
In response to the amendments to the Pharmaceutical Affairs Act, the Committee urges the government to adopt a "risk-based" approach to reporting and intervention. While the goal of preventing drug shortages is shared by all stakeholders, excessive administrative burdens on products with a stable supply history could lead to inefficiencies. Instead, the Committee advocates for a collaborative model where forecast data is used for monitoring rather than punitive measures.
Analysis of Implications for Taiwan’s Global Competitiveness
The recommendations put forward by AmCham Taiwan reflect a broader shift in how healthcare is viewed—not merely as a social cost, but as a strategic investment in national security and economic growth. By aligning with international standards, Taiwan can transform its healthcare system into a powerful engine for the "Five Trusted Industries."
If the government adopts a more predictable and transparent reimbursement mechanism, it is likely to see an uptick in foreign direct investment (FDI) from the pharmaceutical sector. This includes the establishment of more regional R&D centers and manufacturing bases, further integrating Taiwan into the global supply chain. Conversely, maintaining the status quo of aggressive price containment could lead to a "hollowing out" of the innovative drug market, leaving Taiwanese patients with fewer options and the domestic biotech industry with fewer international partners.
In conclusion, the path forward requires a delicate balance between fiscal responsibility and the pursuit of medical excellence. Through deeper public-private collaboration and a commitment to international harmonization, Taiwan has the opportunity to solidify its position as a world-class healthcare leader. The AmCham Pharmaceutical Committee remains committed to this dialogue, viewing the success of the NHI and the prosperity of the pharmaceutical industry as inextricably linked goals that serve the ultimate interest of the Taiwanese people.
Lina Irawan
